XMDC (Nachfolge zu SMMW) Nach Resplit und Neuausrichtung endlich aufwärts! Kurzfristig 100% möglich - 500 Beiträge pro Seite

[boersenphilo2]

XTend Medical Corp (XMDC) | XMDC Quote/Level II-News-Quote-Chart


Free Level II
http://66.201.236.134/export/level2.jsp?symbol=xmdc


XTend Medical Corporation
10771 Sherman Way
Sun Valley, CA 91352
P818) 255-2476
F818) 255-2479

General Inquiries
[e-mail]

Managed Care Sales Pharmacy
[e-mail] [e-mail]

Investor Relations
FutureTech IR
[phone]
[e-mail]

9/26/2007 SMMW Summus Works Inc. Common Stock XMDC XTend Medical Corporation Common Stock 1-8,334 R/S




Summus Announces Corporate Restructure
Company to Change Name, Symbol, and Issue a Reverse Split

SUN VALLEY, Calif., Sept. 17, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Pink Sheets:SMMW) announced the Company has announced a corporate restructure to include a name change, symbol change, and a reverse split of the Company stock, Common and Preferred. The Company issued the following statement:

"As we move the Company forward, it is imperative to have a share structure that will allow us to seek acquisitions as well as targeting an up listing to OTCBB, AMEX, or NASDAQ Small Cap Market within the next year. We will be doing a reverse split at the ratio of 8334 to 1. This adjustment in share structure is intended to decrease our outstanding Common to a more industry standard palatable to future investors, fund managers, our primary Market Makers and for up listing qualifications. Our targeted revenue projections of $60 Million for 2008 and $110 Million in 2009 will insure our current and future shareholders will continue to have value in their investment in the Company. Upon receipt of the confirmation from NASD, we will issue a statement informing the public as to our new symbol," stated Mr. Paul D. Lisenby, Chairman and CEO of Summus. "In addition, the Company will change its name to XTend Medical Corporation to better reflect our position as a major player in the healthcare sector. XTend Medical has been working on several contracts with regional and national health care providers to deliver cutting-edge technologies to insure their patients are monitored and given the best in medical care. The company's main focus is secure long term contracts that will insure the positive growth of the company now and in the future."

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.


CONTACT: FutureTechIR for Summus Works, Inc.
Investor Relations
[phone]
[phone]

[Joe_Trader]

naja , mal abwarten was die nächsten tage passiert.
Stehen jetzt auf meiner watchlist.

[KANTER]

Do issa jaa!!!

[fab35]

Antwort auf Beitrag Nr.: 31.797.769 von KANTER am 30.09.07 19:51:36

Hallo @all.

Bei mir sind se heute umgebucht.

Gruß
fab

[fab35]

Antwort auf Beitrag Nr.: 31.802.121 von fab35 am 01.10.07 11:11:49

Ich würde sagen Totalverlust.
mfg
fab

[fab35]

Antwort auf Beitrag Nr.: 31.819.994 von fab35 am 02.10.07 17:12:07

Zusammenfassung der letzten Ereignisse incl. Bewertung durch den User RJ Trotts aus dem I-Hub Thread.

Hey Ace, great to see you back around. As far as the PPS, based on the r/s, our .0001 shares are converted at .83. And today's PPS is about .12. We tanked on day one, down well below .40, all the way down to a dime. On one day, we hit a .52 HOD, and very quickly fell from that. Our o/s is nice and low, at 65m. That is a very respectable low float. And today's LOI, once again shows that the company X-Tend continues to grow. Also hearing Jose's name in the audio yesterday, and then seeing his name in the PR. I beleive the LOI will be closed here in a matter of days. From the sounds and tone of the PR, it is just a matter of finalizing the paper. Also, of the 65m o/s, most of that is restricted per the CEO confirmed with some emails. The float should be under 10m based on the r/s and the conversion. Dan owned 66% of the o/s, and Paul bought that. I am personally glad the POS Dan is out of the picture. He mislead and sold out us investors. Can Paul get this PPS up and going? IMO, yes is the answer. If he continues to grow the company and the revenues, and does it without dilution. I think the PPS will recover. I am personally averaging down. Since I am one of those that beleive the MM have over-reacted tanking this PPS. And I do NOT think the company is selling BUT it is disgruntled shareholders just getting out at whatever PPS they can get. Let them out. When the dust settles and the revenues are proven, I think we will UPtick nicely with this stock. So I will continue to purchase more shares, to the sellers! GL to you, and thanks for the discounted shares. Several smart investors see a nice PPS increase coming here from this stock. And when the selling pressure STOPS, well the MM will have to increase the PPS to get more shares. That is why I see this PPS climbing out of this area...VERY FAST, once the sellers are done! This stock has rebound all over it!

Grüße
fab

[fab35]

Antwort auf Beitrag Nr.: 31.838.847 von fab35 am 04.10.07 10:34:20

Bin ich noch der einzige hier
Naja, dann führ ich eben Selbstgespräche

XTend Medical (XDMC) Closes on 25% Acquisition of Medical Cost Management, Inc. (MCM)
PR Newswire - October 11, 2007 9:30 AM ET


Related Quotes
Symbol Last Chg
XMDC Trade 0.14 0.00
Quotes delayed at least 15 minutes

XTend Medical Corporation (Pink Sheets: XMDC) announced the company has finalized its due diligence and closed the letter of intent on Medical Cost Management, Inc and has acquired a twenty-five percent stake in the company.

"After completing our extensive due diligence on Medical Cost Management, Inc, we're proud to announce we've acquired a twenty-five percent stake in the company. We felt that it was important to secure a portion of MCM in order for XTend to have a dedicated and focused group of sales and marketing professionals as we work on gaining contracts with managed care companies which happens to be MCM's expertise in the healthcare field. We've also negotiated a first right of refusal to purchase the remaining 75% of the company over the next 2 years through a combination of cash and/or cash and stock," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical Corporation. Mr. Lisenby adds, "This acquisition was done through the issuance of 2,500,000 shares of common stock that came from the original issuance of founder shares in XTend Medical. This will have no effect on the current outstanding shares within the company. XTend will continue to seek out additional acquisition and alliance opportunities that will bring considerable value to the company in order for us to grow and prosper in the healthcare arena."

Medical Cost Management issued the following statement:

"Now that we've closed this deal with XTend, our company will have a much stronger position in securing contracts with our managed care clients. The support we will receive from XTend will assist us in our current negotiations with the managed care companies we currently are in negotiations with. We're excited to be a shareholder in XTend and will work closely with Mr. Lisenby to reach his projections for 2008 and beyond," stated Mr. Jose Santoro, CEO of MCM.

About MCM: Medical Cost Management currently works with several large Managed Health Care companies in the U.S. as well as other regional and local health care insurers throughout the U.S., Puerto Rico, and Canada.

About XTend Medical: XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.

Contact:
Company Contact:
FutureTechIR for XTend Medical Corporation
Investor Relations
[phone]

SOURCE XTend Medical

[gino]

XTend Medical (XMDC) Announces Stock Repurchase Program
Tuesday November 27, 6:31 am ET


Company to Repurchase up to 5M Shares


SUN VALLEY, CA--(MARKET WIRE)--Nov 27, 2007 -- XTend Medical Corporation (Other OTC:XMDC.PK - News) announced the company's Board of Directors has authorized a stock repurchase program and the company will repurchase up to 5 million shares of the Company's common stock. Transactions may occur from time to time, either on the open market or privately negotiated. The stock repurchase is subject to market conditions, corporate and regulatory requirements. The program authorizes the company to repurchase shares of the company's common stock until March 31, 2008 in open market or private transactions. The company has no obligation to repurchase shares under the program and the program may be suspended or terminated at any time.
ADVERTISEMENT


"Consistent with our goal to grow the company and deliver long term shareholder value, we feel this program allows us to be opportunistic in buying shares of our stock when favorable market conditions exist while continuing our strategy of developing several telehealth programs that will be presented, and subsequently implemented, into major health care associations. The shares will be held in the company treasury and used for acquisitions, shareholder dividends, and employee incentive programs. The Board's approval of this program shows a strong belief in XTend Medical and its future. This decision was made based on our consideration of the current share price which our management believes is not indicative of the underlying true value of our company. Based on our projected revenues and the industry average forward P/E ratio of 30, our management believes the share price should be in the $.90 - $1.00 range," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.

About XTend Medical: XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.



Contact:
Contact:
FutureTechIR for XTend Medical Corporation
Investor Relations
[phone]



--------------------------------------------------------------------------------
Source: XTend Medical Corp.

[arubabeachclub]

Entwickelt sich ja prächtig, die neue Gesellschaft

[MaatMod]

Sehr geehrter Wallstreet-online Nutzer,
Hallo,

für eine aktuelle Diskussion enthistorisieren wir diesen Thread.

MfG MaatMOD

[Heftie]

Hallo Leute,
wow, der letzte Monat war ja der Hammer!!



Gratulation an alle, welche unten aufgesammelt hatten.

Für alle, die sich fragen, was denn hier los ist:

Am 1. Oktober 09 wurde ein Merger mit "BioHarp Korea", einer Tochter von Uni Bio-Tech Inc Korea, bekanntgegeben.
Daraufhin explodierte die Aktie an diesem Tag, und befindet sich seitdem in einem stetigen Aufwärtstrend.

[Heftie]

Hier ein klasse Zusammenstellung von iHub User Rainmaker:


PR's: XMDC BioHarp Merger All-in-one-Updated 10/22

XMDC PR's:

XTend Medical (XMDC) Signs Letter of Intent to Merge With BioHarp, Korea
Combined Resources to Target Global Health Markets

SUN VALLEY, CA--(Marketwire - 10/01/09) - XTend Medical, (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, announced today the company has signed a Letter of Intent to Merge with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The share structure of the company will remain in effect with no changes anticipated.

BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body's organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases. This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.

Unlike CT Scans, MRIs and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in increasing morbidity rates and lowering health costs significantly.

The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.

"The management at XTend has been working diligently on this merger for the past 9 months to insure we create a powerful opportunity for the company to have a clear manufacturing partner, cutting-edge medical device, and the market whereby we can sell this device globally to healthcare organizations and countries looking to detect early signs of diseases that will save lives and lessen costs associated with treating these diseases," stated Mr. Paul Lisenby, CEO of XTend Medical. Mr. Lisenby further states, "The BioHarp has gone through several revisions and is now ready to go into full production. The device is not only intended for humans, but the application has shown that animals can benefit from this technology as well. Our goal is to get this device into the hands of physicians, veterinarians, and other professionals that understand the technology can detect, on a molecular level, inflammation that can lead to serious health problems. We will market this product aggressively and have already been contacted by several countries in Asia and Europe that are interested in making the BioHarp part of their national healthcare program. We're very excited to work closely with the doctors and scientists associated with the BioHarp unit in Korea to continue to upgrade the unit for potential use by the general public. We expect to finalize this merger in the next thirty to sixty days."

The company is currently updating their website. www.xtendmedical.com.

About XTend Medical

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at [e-mail]

Letter to Shareholders of XTend Medical (XMDC) From the CEO Regarding the Upcoming Merger With BioHarp, Korea-* On 8:30 am EDT, Tuesday October 6, 2009

SUN VALLEY, CA--(Marketwire - 10/06/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following letter from the CEO, Mr. Paul D. Lisenby, regarding the upcoming merger with BioHarp, Korea and other corporate progress.

"To all XTend shareholders, I want to bring everyone up to date on the upcoming merger with BioHarp, Korea, and to share some insight into the future of the company. As you are aware from our most recent press release, we've decided to merge our company with BioHarp, Korea in order to have one of the most intriguing and cutting-edge medical devices to hit the healthcare industry in decades. The potential for this device to change the way patient diagnostics are currently being done is tremendous. The BioHarp is a non-invasive scanning device that can be used by a trained professional to scan the body to find cellular inflammation, utilizing nano bio-sensors. In layman's terms, whenever there is inflammation in the body on a cellular level, the potential for health issues can result. The BioHarp is a patent protected device that doesn't require any dyes or foreign fluid to be introduced into the body to attain a reading, or better yet, gives the patient results based on their individual body baseline. In short, this device can be used as an early diagnostic device by any country, healthcare company, managed care company, military, and in almost any other situation where an early diagnosis can assist in saving lives and lowering healthcare costs.

The work done by our management team with the principles at BioHarp, Korea, has taken us over two years to get to this point in our relationship wherein we feel comfortable merging with their organization and they feel the same way with us. Our hard work over the past three years in dealing with managed care companies, physician groups, and other healthcare organizations will prove to be most beneficial in securing future contracts for the BioHarp once the merger is complete. BioHarp, Korea has spent the last 14 years working on bringing the BioHarp unit to its current level of perfection and by combining our resources we gain solid management, premiere manufacturing, and the potential for a global company that will make BioHarp the most used medical device in early diagnosis.

There was a press release in February 2008, issued by Hathaway Corporation, announcing a joint venture with UNI Bio-Tech for the BioHarp device. As I was with the company at that time acting as the interim CEO, I knew the value of BioHarp. However, since the Board of Directors of Hathaway decided to change their business model to become FutureWorld Energy and focus their efforts on the renewable energy sector, the joint venture never took place and the deal was cancelled in April of 2008. My work with Hathaway has since stopped and for the last 18 months my sole responsibility has been to ensure XTend Medical brings value to our shareholders and puts itself in a position to capitalize on opportunities to grow the company. Through this merger, the company will become a global leader in the healthcare sector and it will be up to all of us here at XTend Medical and BioHarp, Korea to ensure that this happens.

Since the announcement of this merger, we have been working hard with Pink Sheets to become fully compliant with their reporting requirements. We should have this accomplished by week's end and hopefully have the Stop Sign removed from our company's profile. Our goal is to move up to a greater exchange due to the potential sales that we anticipate the BioHarp will be doing globally very soon. We are working with our accountant and legal teams to ensure that we have everything in order so the migration to a higher exchange can be accomplished at the proper time. Any changes we've recently made to the corporate structure are to effectuate this merger and any and all shares issued for this merger are subject to Rule 144 Restrictions. As we update Pink Sheets, the information will be there for all shareholders to review. We are in the process of updating our site and will share additional information about our progress in future press releases. In closing, I would like to thank all of our loyal shareholders for their dedication and for potential future shareholders; this company will be strong and have a very bright future for many years to come."

XTend Medical (XMDC) Discusses BioHarp Market Potential and Revenue Model

SUN VALLEY, CA--(Marketwire - 10/12/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the BioHarp market potential:

"As the company moves closer to completing the merger with BioHarp Korea, the management feels it is vital for our shareholders to understand the market potential and the revenue model of the BioHarp device. The BioHarp unit market potential stretches globally. There has been interest from several health departments globally to deploy the BioHarp to outlying village areas and major metropolitan healthcare clinics to utilize the BioHarp as an effective tool for pre-diagnosis on regular physical appointments. Since the BioHarp can travel anywhere with a laptop, the ability for these countries to deploy the unit to hard to get geographical areas allows these countries to scan the patient and choose the correct follow-up procedures that can save these countries millions of dollars in healthcare costs. These countries will use the five sensor unit and the software will be integrated into their respective national healthcare databases.

"In addition to the human markets, the BioHarp will be marketed to the pet and equine industries. The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets in order to discover potential harmful conditions that can be treated through nutrition and medications. The ability for the veterinarian to market this as an added service allows them to create an additional revenue stream as well as giving pet owners the ability to monitor their pet's health and hopefully alleviate costly procedures. The equine industry itself can be very lucrative for the company in the future. The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised. As the BioHarp unit can be deployed to the stables, part of their post exercise routine would be for the trainer or vet to scan the horse upon completion of their workout or race and determine if there is any underlying inflammation that can lead to being sidelined, thereby eliminating the ability to earn money racing. This market alone is global in nature as there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners. The yearling sales at places like Keenland, wherein owners plunk down millions to own a potential Triple Crown winner, would benefit by having a BioHarp scanner available in order to scan potential champions to insure the fitness of the horse and to detect potential problems that could arise in the future. These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company.

"The revenue model for the BioHarp comes from both the hardware and software sales. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. Naturally, if we have groups that are purchasing thousands of units, we will have a discount structure to these monthly fees. With the patient potential in the millions, our revenue model will be very strong and consistent for years to come.

"Lastly I would like to touch on our corporate structure and how we feel the share structure will be beneficial for all current and future shareholders of the company. We strongly feel that our Authorized shares at this time are sufficient to handle our merger and capital raise needs. We feel it would be disadvantageous to do any sort of reverse split due to the potential sales of the BioHarp unit in the coming years. If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we've received, the company's market cap will be substantial," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

XTend Medical (XMDC) Updates Shareholders on Merger and Company's Progress
Font size: A | A | A
8:31 AM ET 10/22/09 | Market Wire

XTend Medical (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the company's progress on merger and company's progress:

"XTend would like to update our shareholders on our progress to date. Mr. Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend. The meetings were very positive and included several aspects in the manufacturing process and the business model moving forward. I personally want to thank Mr. Lee for his dedication and efforts in moving the merger forward. The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger. We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company. While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.

The combined efforts of the seasoned technical team in Korea with the management in the U.S. will insure that the BioHarp device will become the standard in medical diagnosis. Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally. As we move forward, these opportunities will be explored and if they benefit the company, we will press forward on a working relationship.

As to the BioHarp unit itself, I would like to reiterate a few areas that make this device unique:

1. The BioHarp requires a pre-scan of the patient in order to get a baseline reading. This baseline reading is not based solely on a set of standards in the medical sector. These individualized baselines are established from the patient's own cellular makeup and further solidify how the BioHarp sets itself apart from any present of future competitors.

2. The BioHarp device is completely portable. Unlike CT Scanners and other large pieces of equipment that remain stationary, the BioHarp can travel to where the patients are. The unit is perfect for rural areas, battlefields, or other outlying areas that would benefit by having the BioHarp as part of their healthcare service.

3. BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.

4. The dedication Mr. Lee has spent on this device over the past 14 years is truly incredible. His vision for this device has proven instrumental in the development of the BioHarp. His technical staff has, and continues t, spend countless hours perfecting this product and we feel honored to become part of this exciting and truly unique product.

In closing, I would like to thank all of our shareholders for being patient as we close this merger. Mr. Lee and I have worked continuously over the past two years to insure you, as shareholders, will reap the benefits of being part of something we're very proud of. The future is very bright for this company and through hard work and dedication, the BioHarp will flourish and become the leading diagnostic device in the global medical community," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

About XTend Medical

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at [e-mail]

The new website can be located at www.bioharpunius.com

[Heftie]

BioHarp Patente:

Schritt 1: Auf Seite http://appft.uspto.gov/netahtml/PTO/search-bool.html gehen

Step 2: Eine der folgende Patentnummer in Feld "Term 1" eingeben und "search" klicken. Eines ist für die Sensortechnik von BioHarp, das andere über die komplette Hard- und Software des BioHarp Systems.


20090182218

oder

20090137895

[Heftie]

Ein paar Pics von dem Gerät:

http://bioharpunius.com/Picture_Gallery.html

[Heftie]

Gap up heute, bereits 2 Mio $ Umsatz in den ersten 2 Stunden!

Xtend Medical Cor (USOTC:XMDC)
Last Price (USD)
$ 0.0825
Change
▲ 0.0275 (50.00%)
Bid 0.083
Ask 0.084
Volume 22,826,349
Day\'s Range 0.068 - 0.089
Last Trade 8:30:13 AM EDT

[Heftie]

Sonst keiner da?
Egal, dann spiele ich so lange den Alleinunterhalter

[Stayc]

Hallo, wo kaufst du diese Aktie? Kann sie nämlich bei Comdirect nicht kaufen.
Bei Cortal consors vielleicht?

[Heftie]

Jepp, Consors.
Da geht so ziemlich alles, sofern die Aktie eine WKN hat.


Schöne Konso heute, die Aktie war die letzten Tage ziemlich überhitzt!

[Heftie]

Schöner Freitag!

Ob wohl der CEO dieses Wochenende den Merger mit BioHarp in Korea klar macht?

Eine entsprechende PR Montag wäre der Knüller

[1upandaway]

Authorized Shares 1,000,000,000
Total Shares Outstanding 616,737,031
Public Float 299,065,600
http://www.pinksheets.com/otciq/ajax/showFinancialReportById…

werd mir ein paar stügge ins depot legen, kann nicht schaden

[1upandaway]

Antwort auf Beitrag Nr.: 38.476.371 von 1upandaway am 29.11.09 21:09:56

bin gestern mit ein paar stüggen rein, heisse phase beginnt

SUN VALLEY, CA and SEOUL, KOREA--(Marketwire - 11/18/09) - XTend Medical, (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company is in the final stages of completing the merger between XTend Medical Corporation and BioHarp, Korea.

The company issued the following statement: "We're proud to announce XTend has finished their meetings in Korea with BioHarp. While we originally intended to just merge operations, XTend feels it will be in the best interest to purchase the assets wherein the newly merged entity would own the BioHarp medical device in its entirety. This insures the company has sufficient assets for proper company valuation as we look to begin the process of moving to a higher exchange. As this will involve both securities and cash, it is imperative to properly investigate any tax implications or other fees that may have an affect on both companies to insure the company is following proper procedures for the regulatory agencies. We will consult with our corporate counsel and CPA to insure we protect the company and complete this with the proper documentation and approvals. Mr. Lee will be traveling to Los Angeles at the beginning of December to meet with us to discuss the operational aspects of the new entity as we move forward," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

die nächsten 2 wochen sollten wir positives zu hören bekommen
http://stockcharts.com/h-sc/ui?s=xmdc

[1upandaway]

auffi gehts

XTend Medical Corporation (XMDC) Finalizes Asset Purchase With BioHarp, Korea

SUN VALLEY, CA--(Marketwire - 12/09/09) - XTend Medical, (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company has completed and signed the asset purchase agreement with BioHarp, Korea.

The company released the following statement, "Mr. Lee, Mr. Friedman, and I are pleased to announce the completion of the asset purchase agreement between XTend Medical and BioHarp, Korea. The process took a little longer than anticipated but we're extremely excited to finalize this agreement and work together with Mr. Lee to begin the manufacturing, marketing, and sales of the BioHarp device. XTend Medical has an incredible asset that will insure the company's valuation moving forward. The device will, in our opinion, be known very soon as the premier medical diagnostic tool worldwide. We're thoroughly impressed with the team behind the BioHarp and are looking forward to a long lasting relationship. XTend Medical will move quickly to gain sales in Korea, China, Japan, and other countries that have expressed interest in the unit and to have a combined operation so our reach is global in nature. We anticipate the sales of the BioHarp to reach phenomenal numbers in the coming years," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

Mr. Lee, CEO of BioHarp, Korea, added, "I am extremely excited about the future of the BioHarp. Our team, combined with the management of XTend Medical, will insure the company's success. We look forward to working closely with Mr. Lisenby and Mr. Friedman as we begin the manufacturing and sales process globally and deploy the BioHarp to health organizations throughout the world."

[1upandaway]

dürft 2010 ein richtiger kracher werden
heut wieder news, wenns so kommt wies das steht

mein stügge bleiben voerst mal liegen bis der dollar kommt

[1upandaway]

XMDC Wishes for 2010

*Manufacturing Partner announced
*KFDA Approval announced
*FDA Approval announced
*Medical Device manufacturing partners announced
*BioHarp sales begin in Korea
*BioHarp sales begin in China
*BioHarp sales begin in Japan
*BioHarp sales begin in US
*Name and Symbol change- New Symbol HARP
*XMDC files audited financials with SEC
*Research partnerships with major US Hosptials & Universities announced
*Contracts with Government Health Care agencies announced
*BioHarp scanning centers begin to open at Racetracks across America
*XMDC uplists to otcbb
*BioHarp featured on 60 minutes TV show
*First BioHarp training centers open for business
*Joint studies announced with several universities to utilize the BioHarp in their studies of crops and plants
*Miltary contracts announced to utilize BioHarp
*First sales to Veterinarians announced
*First 20,000 BioHarps ship to China and Japan

[1upandaway]

Antwort auf Beitrag Nr.: 38.654.566 von 1upandaway am 02.01.10 14:41:58

BioHarp is comming ...
http://www.bioharpunius.com/Home_Page.php

[1upandaway]

Antwort auf Beitrag Nr.: 38.714.135 von 1upandaway am 12.01.10 07:23:56

tic toc ....
auf ein news- und kursfeuerwerk die nächsten wochen/monate

mein ziel für 2009 liegt bei 20-50 cent

[1upandaway]

Antwort auf Beitrag Nr.: 38.761.508 von 1upandaway am 19.01.10 08:53:21

wird langsam zeit ...